Kush Parmar
Affiliations
- at Entrada Therapeutics Inc. (TRDA), 2025-07-11
- Large Shareholder at Camp4 Therapeutics Corp (CAMP), 2024-10-15
- Large Shareholder at Skye Bioscience Inc. (SKYE), 2024-09-13
- Large Shareholder at Artiva Biotherapeutics Inc. (ARTV), 2024-07-24
- Director at Rallybio Corp (RLYB), 2024-05-17
- Large Shareholder at Enliven Therapeutics Inc. (ELVN), 2024-02-16
- Large Shareholder at Cincor Pharma Inc. (CINC), 2023-02-28
- Large Shareholder, Director at Akouos Inc. (AKUS), 2022-12-02
- Director at Homology Medicines Inc. (FIXX), 2022-06-17
- Large Shareholder, Director at Vor Biopharma Inc. (VOR), 2022-06-16
- Large Shareholder at Cabaletta Bio Inc. (CABA), 2021-11-03
- Large Shareholder at Impel Neuropharma Inc (IMPL), 2021-04-30
- Co-Ceo at 5:01 Acquisition Corp. (FVAM), 2020-12-01
- Other at Aprea Therapeutics Inc. (APRE), 2020-10-08
- Director at Arvinas Inc. (ARVN), 2019-09-26
- Director at Scpharmaceuticals Inc. (SCPH), 2018-06-21
- Director at Audentes Therapeutics Inc. (BOLD), 2018-06-08
Insider Trading: Purchases See All
| Symbol | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| TRDA | $20.00 | 250,000 | $5,000,000.00 | 1,132,357 | 2021-11-02 | Filing |
| RLYB | $13.00 | 615,384 | $7,999,992.00 | 1,406,098 | 2021-08-02 | Filing |
| VOR | $18.00 | 444,444 | $7,999,992.00 | 1,858,470 | 2021-02-09 | Filing |
| VOR | $18.00 | 111,111 | $1,999,998.00 | 4,833,959 | 2021-02-09 | Filing |
| AKUS | $17.00 | 294,117 | $4,999,989.00 | 1,094,101 | 2020-06-30 | Filing |
Insider Trading: Sales See All
| Symbol | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| TRDA | $7.50 | 6,935 | $52,026.37 | 1,093,313 | 2025-07-09 | Filing |
| TRDA | $7.50 | 20,065 | $150,527.63 | 3,163,066 | 2025-07-09 | Filing |
| TRDA | $7.12 | 6,422 | $45,741.34 | 1,100,248 | 2025-07-01 | Filing |
| TRDA | $7.12 | 18,578 | $132,323.66 | 3,183,131 | 2025-07-01 | Filing |
| TRDA | $6.81 | 6,422 | $43,751.16 | 1,106,670 | 2025-06-30 | Filing |